Table 3.
Factors associated with an optimal haplo-identical donor-derived myeloid bridge after haplo-dCBT (n=75)*.
| Variables | N | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |||
| Haplo-CD34+ characteristics | ||||||
| Cryopreserved haplo-CD34+ graft | Yes No |
11 64 |
reference 1.54 (0.42–6.38) |
0.52 | - | |
| CD34+ cell dose/kg | continuous | - | 1.17 (1–1.38) | 0.059 | 1.20 (1.01–1.47) | 0.047 |
| CD3+ cell dose/kg# | continuous | - | 1.28 (0.68–2.43) | 0.445 | - | |
| Haplo-recipient 8-allele HLA-match | 4/8 5–7/8 |
59 16 |
reference 3.4 (1.1–12.1) |
0.04 | reference 3.11 (0.91–11.92) |
0.079 |
| DSA against haplo-identical donor | No Yes |
65 10 |
reference 3.28 (0.83–16.31) |
0.11 | ||
| Dominant CB unit characteristics | ||||||
| TNC dose/kg | continuous | - | 1.02 (0.51–2.02) |
0.953 | - | |
| CD34+ cell dose/kg | continuous | - | 1.0 (0.5–2.2) | 0.967 | - | |
| CD3+ cell dose/kg | continuous | - | 1.1 (0.8–1.5) | 0.677 | - | |
| Unit-recipient 8-allele HLA-match | < 5/8 ≥ 5/8 |
28 47 |
reference 0.74 (0.3–1.9) |
0.531 | - | |
| Unit-haplo 8-allele HLA-match | < 3/8 ≥ 3/8 |
35 40 |
reference 2.95 (1.16–7.84) |
0.026 | reference 3.49 (1.27–10.42) |
0.019 |
| Non-dominant CB unit characteristics | ||||||
| TNC dose/kg | continuous | - | 1.18 (0.69–2.06) | 0.546 | - | |
| CD34+ cell dose/kg | continuous | - | 0.78 (0.37–1.55) | 0.482 | - | |
| CD3+ cell dose/kg | continuous | - | 0.98 (0.68–1.42) | 0.931 | - | |
|
Unit-recipient 8-allele HLA-match |
< 5/8 ≥ 5/8 |
30 45 |
reference 0.91 (0.36–2.32) |
0.85 | - | |
|
Unit-haplo 8-allele HLA-match |
< 3/8 ≥ 3/8 |
35 40 |
reference 0.78 (0.31–1.95) |
0.598 | - | |
*
Success of optimal myeloid bridge was evaluated only in patients who achieved sustained CB engraftment (n = 75)
#
log-transformed due to skewness